US

Showing 15 posts of 324 posts found.

takeda_deerfield_hq

Takeda plans to vacate all 1,000 staff from US HQ by the year’s end

June 26, 2019
Manufacturing and Production, Medical Communications, Sales and Marketing Shire, Takeda, US, pharma

Takeda has announced its plans to vacate all staff from its US headquarters in Deerfield, Illinois, by the end of …

FDA knocks back Glenmark’s allergic rhinitis therapy Ryaltris

June 25, 2019
Manufacturing and Production, Sales and Marketing FDA, Glenmark, Ryaltris, US, allergy, pharma

Stocks in Indian pharmaceutical firm Glenmark were sent plummeting to a six-year low after it was confirmed that the FDA …

merck-keytruda

MSD’s Keytruda snatches up first approval in small cell lung cancer

June 19, 2019
Research and Development, Sales and Marketing Cancer, FDA, MSD, US, keytruda, lung cancer, pharma

MSD has revealed that its anti-PD-1 immunotherapy Keytruda (pembrolizumab) has been awarded marketing authorisation from the FDA as a monotherapy …

fda2outsideweb

FDA advisory panel backs TB Alliance’s tuberculosis regimen

June 10, 2019
Sales and Marketing FDA, TB Alliance, US, pharma, tuberculosis

An FDA advisory panel has voted to recommend the investigational drug pretomanid, developed by the non-profit organisation TB Alliance, as …

donald_trump-_image_credit_gage_skidmore

Donald Trump causes confusion as to whether NHS will be ‘on the table’ in trade deal talks

June 6, 2019
Business Services, Medical Communications Donald Trump, NHS, UK, US, healthcare, pharma

President Donald Trump has caused confusion as to whether or not the NHS will ‘be on the table’ in post-Brexit …

Healthcare would be ‘on the table’ in post-Brexit trade negotiations with US, Trump’s ambassador says

June 3, 2019
Sales and Marketing J&J, JJ, NHS, UK, US, brexit, healthcare

The American Ambassador to the United Kingdom has said that Britain’s healthcare system would be ‘on the table’ in post-Brexit …

gsk_boronia_australia

GSK to reintroduce bonuses for sales reps

May 24, 2019
Medical Communications GSK, US, oncology, pharma, sales, sales reps, scandal

British multinational GlaxoSmithKline said on Thursday that it would reintroduce performance-based bonuses for some sales reps in some countries. The …

chinese_flag_beijing_-_img_1104

Chinese pharmaceuticals will not be subject to tariffs, US Trade Representative says

May 14, 2019
Manufacturing and Production China, US, USTR, pharma, tariffs, trade

The Office of the United States Trade Representative (USTR) has said pharmaceuticals will not be subject to potential US tariffs …

fda2outsideweb

FDA to end controversial “alternative summary reporting” of medical devices in bid to boost transparency

May 10, 2019
Medical Communications, Research and Development, Sales and Marketing FDA, US, adverse events, medical devices, pharma

The FDA has revealed that it plans to terminate its “alternative summary reporting” programme which has allowed the manufacturers of …

US prescription drugs most expensive in world, analysis shows

May 8, 2019
Research and Development Drug pricing, Japan, Ontario, UK, US, prescription drugs

Brand name prescription drugs cost on average 4.3 times more in the United States than in the UK, according to …

FDA approves first two drugs for transthyretin amyloid cardiomyopathy

May 7, 2019
Manufacturing and Production, Sales and Marketing FDA, Pfizer, US, Vyndamax, Vyndaqel, pharma

The FDA has approved its first two therapies for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), …

gsk_boronia_australia

GSK’s Benlysta becomes first FDA-approved IV therapy for paediatric lupus

April 30, 2019
Manufacturing and Production, Sales and Marketing Benlysta, FDA, GSK, Lupus, US, pharma

GSK has scored approval in the US with Benlysta (belimumab) for the treatment of systemic lupus erythematosus (SLE) in paediatric …

abbvie_0

AbbVie’s Skyrizi snatches up FDA approval in moderate to severe plaque psoriasis

April 24, 2019
Research and Development, Sales and Marketing AbbVie, FDA, Skyrizi, US, pharma, psoriasis

AbbVie has revealed that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab-rzaa) has received marketing authorisation in the US from the FDA …

Clovis Oncology discontinue phase 2 bladder cancer trial

April 15, 2019
Sales and Marketing Cancer, Clovis Oncology, US, bladder cancer, metastatic bladder cancer

Colorado-based pharma firm Clovis Oncology has said in a filing to the US Securities and Exchange Commission that it is …

opioid_pills

Opioid crisis cost US government nearly $38 billion in lost taxes

April 11, 2019
Medical Communications, Research and Development US, government, opioid crisis, opioids, public health, tax revenue

The opioid epidemic may have cost US state and federal governments as much as $37.8 billion in lost tax revenue, …

The Gateway to Local Adoption Series

Latest content